Mammary gland

HME1

Evercyte ́s human mammary epithelial cell line HME1 can be grown without limitations while maintaining expression of cell type specific markers and functions. Therefore, these cells are useful as standardized in vitro model to study processes such as breast cancer development, to test anti-tumor therapies or to perform toxicological tests.

Additionally, the cell line is the perfect starting material for genetic engineering to create important disease models.

from

€ 1600,–

HME1
Cat#: CHT-044-0236

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO

Related Services

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about
our cells

news

Lecture on 3Rs

(replacement – reduction -refinement of animal experiments)

Related Products

telomerized cells from different tissues and organs

Related Services

generation of human continously growing cells for setting up relevant and standardizable in vitro test systems

telomerized human lung fibroblasts

coming soon

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

from

€ 1300,–

HME1
Cat#: CHT-044-0236

ONLY FOR NON PROFIT

FOR PROFIT INDUSTRY

FOR PROFIT-CRO